ORIC Targets 2027 Phase 3 Trial for Enozertinib After ESMO Data
ORIC Pharmaceuticals, Inc. disclosed on October 23, 2026, that it plans to initiate Redwood-1, a global Phase 3 clinical trial for enozertinib in first-line EGFR atypical non-small cell lung cancer, during the first half of 2027. The company included these plans in an exhibit to a Current Report on Form 8-K filed with the Securities and Exchange Commission, which detailed a program update for its lead product candidate. This announcement follows the presentation of clinical data from the ESMO 2026 conference, where ORIC reported efficacy benchmarks for enozertinib in a global patient population with a high prevalence of baseline central nervous system disease.
ORIC Pharmaceuticals, Inc. disclosed on October 23, 2026, that it plans to initiate Redwood-1, a global Phase 3 clinical trial for enozertinib in first-line EGFR atypical non-small cell lung cancer, during the first half of 2027. The company included these plans in an exhibit to a Current Report on Form 8-K filed with the Securities and Exchange Commission, which detailed a program update for its lead product candidate. This announcement follows the presentation of clinical data from the ESMO 2026 conference, where ORIC reported efficacy benchmarks for enozertinib in a global patient population with a high prevalence of baseline central nervous system disease.
In the reported data, enozertinib achieved an 84% confirmed objective response rate for systemic disease and a 70% confirmed objective response rate for central nervous system disease, with multiple complete responses observed in the CNS cohort. The six-month landmark progression-free survival rate stood at 88%. ORIC characterized the safety profile as competitive, noting the absence of significant off-target toxicity and no treatment-related discontinuations. The company described the first-line EGFR atypical NSCLC segment as a market opportunity exceeding $2.5 billion in the United States, stating that the current therapeutic landscape lacks a best-in-class agent with meaningful systemic efficacy, compelling CNS activity, and favorable tolerability.
The 8-K filing identified several executives and key opinion leaders who participated in the program update presentation. Jacob Chacko served as Chief Executive Officer, while Lori Friedman held the position of Chief Scientific Officer. Pratik Multani acted as Chief Medical Officer, Dominic Piscitelli as Chief Financial Officer, and Matt Panuwat as Chief Business Officer. Keith Lui was identified as Senior Vice President of Commercial and Medical Affairs. Dr. Joshua Sabari, an Assistant Professor of Medicine at NYU Grossman and an investigator in the enozertinib trial, also participated as a guest key opinion leader.
The company cautioned that the presentation contained forward-looking statements involving substantial risks and uncertainties, including those related to clinical trial timing, regulatory approvals, and commercialization. ORIC stated that it does not guarantee future results and that actual outcomes may differ materially from its expectations. The product candidate remains under clinical study and has not yet received marketing approval from the U.S. Food and Drug Administration.